Compare Novo Nordisk A/S (NVO) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Upstart Holdings Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Upstart Holdings Inc trades at $29.27 (market cap $2.76B). The key difference: Novo Nordisk A/S is far larger — about 79.9× Upstart Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| NVO | UPST | |
|---|---|---|
Market Cap | $220.53B | $2.76B |
Sector | Health | Financials |
52-Week High | $71.70 | $84.13 |
52-Week Low | $35.29 | $24.22 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Upstart Holdings (UPST) trades at $29.27, down 0.81% on the day, with a bearish technical signal but improving fundamentals. The company reported a net income of $53.60 million in 2025, marking a significant turnaround from prior losses. Recent news highlights AI-driven lending growth and a $600 million funding deal with Neuberger Berman, though quarterly earnings have been mixed with a recent miss in Q1 2026.
The stock presents a high-risk, high-reward opportunity, supported by analyst consensus targets near $42.00 but challenged by volatile cash flows and rising debt. Key risks include execution on new loan products and macroeconomic sensitivity, while institutional sentiment remains divided with a 45% buy rating. Near-term direction hinges on Q2 2026 results due August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
